Loading treatment…
Compounded — not FDA-approvedPrescription only
Compounded CJC-1295 / Ipamorelin
Compounded — nightly injection
A compounded nightly injection pairing a long-acting GHRH analogue with a selective ghrelin-receptor peptide, both of which prompt your own pituitary to release growth hormone. Neither is on FDA's compounding list.
CJC-1295 and ipamorelin are not FDA-approved drugs and are not currently on FDA's list of substances that may be used in compounding. FDA's advisory committee voted against including CJC-1295 on 2024-12-04 and against ipamorelin on 2024-10-29; their status may change and this treatment may be withdrawn. Your provider decides whether it is appropriate for you.
From$199/mo$32 consultation included, not refunded · medication and shipping if prescribed
Choose your plan
4-week supply
Price
$199for a 4-week supply, if prescribed
Includes your $32 provider consultation (non-refundable). If your provider decides treatment isn’t appropriate, the medication portion is refunded automatically.
- Your provider confirms the dose. If they start you on a lower step, we refund the difference; if they choose a higher one within the same plan, the price you paid stands.
Adding to cart books a provider visit. You pay the shown total; the provider decides; the medication portion comes back automatically if they say no.
Questions
Will I definitely be prescribed this?
No. A consultation does not guarantee a prescription. A licensed provider reviews your history at the visit and decides whether this is appropriate for you; because the substance is not on FDA's list for compounding and the human data is thin, many providers will reasonably decline. If they decline, the medication portion of what you paid is refunded automatically; the consultation fee is not.
Is this FDA-approved?
No. Compounded drugs are not FDA-approved, and neither CJC-1295 nor ipamorelin is the active ingredient of any approved product — they are not currently on FDA's list of substances that may be used in compounding. FDA has not reviewed either of them, or this combination, for safety, effectiveness or quality.
Could this be withdrawn?
Yes. Its regulatory status can change at any time: FDA's advisory committee vote is a recommendation, FDA's own rulemaking decides the list, a state pharmacy board can act on its own, and our partner pharmacy can stop preparing it. If any of that happens we stop offering it, tell you, and refund the medication portion of any order the pharmacy can no longer fill.
Why did FDA's committee vote against these?
Because the nominators could not show the committee enough evidence of safety or effectiveness for the uses proposed — growth hormone deficiency for both, plus postoperative ileus for ipamorelin. The votes were 0 to 13 on CJC-1295 in December 2024 and 0 to 12 with one abstention on ipamorelin in October 2024. The committee advises; FDA's own rulemaking sets the list, and until it does these substances are simply not on it.
Is this the same as taking growth hormone?
No. Growth hormone injections deliver the hormone itself and override your feedback loops; these two peptides ask your pituitary to release it, and your own regulation stays in charge. That is a pharmacological difference, not evidence about results — nobody has measured results for this pairing.
How it works
CJC-1295 is a modified fragment of growth-hormone-releasing hormone (GHRH) engineered to survive far longer in the blood; in the 2006 study in healthy adults a single injection raised growth hormone and IGF-1 for days rather than minutes. Ipamorelin is a five-amino-acid peptide that acts on the ghrelin receptor — a second, separate input to the same pituitary cells — and in the animal work that introduced it released growth hormone without the cortisol and prolactin rise seen with earlier peptides in its class. The pairing is the logic: one signal raises the size of each growth-hormone pulse, the other adds pulses, and your own feedback loop still applies because the pituitary, not a syringe of growth hormone, is doing the releasing. What the logic does not supply is outcome data. No trial has tested the combination in people for recovery, sleep, body composition or anything else; FDA's advisory committee found the evidence for each component insufficient for compounding, and that is the honest state of the science.
The full mechanismWhat the trials found
Published results, with what each was measured against.
These results come from trials of the FDA-approved product named in each citation. The compounded preparation on this page is not that product, was not studied in these trials, and has not been reviewed by the FDA for safety, effectiveness or quality.
Growth hormone raised 2- to 10-fold for six days or more, and IGF-1 1.5- to 3-fold for nine to eleven days, after a single injection of CJC-1295
vs each participant's own pre-dose level, in healthy adults
A dose-ranging study of the single ingredient in healthy volunteers. It measured hormone levels, not recovery, sleep, body composition or any outcome a patient would notice, and no trial of the combination with ipamorelin exists.
Teichman et al., J Clin Endocrinol Metab 2006;91(3):799–805
Trial averages describe a study population, not a prediction for you. Your provider will be direct about what is realistic given your history — and results depend on continuing treatment.
A provider may consider it if
- Recovery, sleep quality and body composition are the goals you are working on with a provider, and you understand the human data is thin
- You would rather prompt your own pituitary than inject growth hormone itself
- You can commit to a nightly subcutaneous injection and to check-ins where your provider asks whether it is earning its place
It won’t be prescribed if
- Active cancer, or a history of cancer, without your oncologist involved — raising growth hormone and IGF-1 is exactly what you do not want near a tumour
- Pregnancy, breastfeeding or trying to conceive
- Diabetes or prediabetes without your prescriber involved — growth hormone raises blood glucose
- Pituitary disease, or untreated thyroid or adrenal conditions, which change how the axis it works through responds
- Under 18 — growth plates are still open
- Anyone who needs a treatment with human outcome data behind it: this combination has none
These are the same checks your provider runs in the visit. If one applies, they will tell you plainly — and the medication portion of what you paid comes back automatically.
What to expect
Weeks 1–4
Injection-site redness or a small bruise is the common early experience. Some people report vivid dreams, flushing, water retention or increased hunger — ipamorelin acts on the hunger hormone's receptor.
Months 2–3
The earliest point at which your provider can honestly assess anything. Human outcome data is limited to short studies of the single ingredients, so the assessment is yours and theirs, not a trial's.
Ongoing
Reviewed at check-ins like any prescription; your provider may ask for IGF-1 and fasting glucose bloodwork. Its regulatory status can change, and if it does we stop offering it and tell you.
Safety
Side effects, before you decide
Injection-site redness, itching, pain or bruising are the common ones. Flushing, headache, dizziness, water retention, joint aches, tingling in the hands, increased hunger and vivid dreams are reported with peptides in this class. Raising growth hormone can raise blood glucose and IGF-1, and the effects of doing that for months are not characterised. Human outcome data is limited to small, short studies of each component alone; no safety study of the combination exists.
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. J Clin Endocrinol Metab 2006;91(3):799–805 — CJC-1295 in healthy adults: half-life of 5.8–8.1 days, growth hormone and IGF-1 raised for days after a single dose
- Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Eur J Endocrinol 1998;139(5):552–561 — ipamorelin, the first selective growth hormone secretagogue: animal data showing growth hormone release without the ACTH, cortisol or prolactin rise seen with GHRP-6 and GHRP-2
- FDA Pharmacy Compounding Advisory Committee, briefing documents and final summary minutes, 2024-10-29 (ipamorelin) and 2024-12-04 (CJC-1295)
Complete safety information is provided during your visit and with every prescription. This page is a summary, not a substitute for your provider's advice.
Also for peptides
Compounded Tesamorelin / Ipamorelin
Compounded MOTS-cFrom$239/mo$32 consultation included, not refunded · medication and shipping if prescribed
Compounded MOTS-c / Tesamorelin
Compounded EpithalonFrom$349/12 wk$32 consultation included, not refunded · medication and shipping if prescribed
Compounded Epithalon / GHK-CuFrom$219/mo$32 consultation included, not refunded · medication and shipping if prescribed
Compounded Semax / Selank
Compounded DSIP (Delta Sleep-Inducing Peptide)
Compounded Thymosin Alpha-1
Compounded Pinealon / PE-22-28 / Selank
See whether compounded cjc-1295 / ipamorelin is right for you.
A licensed provider reviews your visit and decides. You receive medication only if prescribed, and that portion of your payment is refunded automatically if they say no.